Pitolisant

證據等級: L5

預測適應症: 3 個

Pitolisant: From Narcolepsy to Insomnia

One-Sentence Summary

Pitolisant is a first-in-class selective histamine H3 receptor inverse agonist, approved internationally (Europe and USA) for the treatment of narcolepsy with or without cataplexy. The TxGNN model predicts it may be effective for Insomnia, with 1 clinical trial (withdrawn, zero enrollment, and not even targeting insomnia) and 8 publications retrieved — however, virtually all literature addresses narcolepsy or excessive daytime sleepiness. Pitolisant's established wake-promoting mechanism is fundamentally opposite to what insomnia treatment requires, making this a likely false-positive prediction driven by disease graph proximity rather than genuine pharmacological plausibility.

Quick Overview

Item	Content
Original Indication	Not locally registered; approved internationally for narcolepsy with or without cataplexy
Predicted New Indication	Insomnia
TxGNN Prediction Score	99.71%
Evidence Level	L4
Italy Market Status	Not marketed
Number of Authorizations	0
Recommended Decision	Hold

Why is This Prediction Reasonable?

Currently, detailed mechanism of action data is not available in this Evidence Pack. Based on the retrieved literature, Pitolisant is a selective histamine H3 receptor inverse agonist. By blocking H3 autoreceptors on histaminergic neurons in the posterior hypothalamus, Pitolisant prevents tonic autoinhibition of histamine release, thereby increasing histaminergic neurotransmission throughout the brain. Downstream activation of postsynaptic H1 receptors promotes arousal and wakefulness. This is precisely why Pitolisant is efficacious in narcolepsy — a disorder defined by pathological inability to maintain wakefulness.

This mechanism is, however, pharmacologically opposite to what is required for insomnia treatment. Insomnia calls for sleep promotion, not wake promotion. It is no coincidence that the well-established sedative-hypnotics in clinical use — including doxepin, diphenhydramine, and the antihistamine class broadly — work as H1 receptor antagonists, dampening histaminergic activity to facilitate sleep. Pitolisant amplifies that same system in the exact opposite direction. A review in Current Neuropharmacology (PMID 34521328) explicitly contrasts H3R inverse agonist pitolisant (wakefulness) against H1R antagonist doxepin (insomnia treatment), underscoring this mechanistic dichotomy.

The TxGNN model assigned an exceptionally high score (99.71%) to this prediction, which most likely reflects the topological proximity of narcolepsy and insomnia nodes within the biomedical knowledge graph — both are classified as sleep disorders and share overlapping phenotypic descriptors. This is a recognized limitation of graph-based repurposing models: they can identify structural closeness without capturing the directional nature of a drug's pharmacodynamic action. This prediction is assessed as a probable false positive and does not warrant clinical development without a compelling mechanistic reframe.

Clinical Trial Evidence

Trial Number	Phase	Status	Enrollment	Key Findings
NCT02800083	Phase 2	Withdrawn	0	Targeted alcohol use disorder, not insomnia — primary endpoint was reduction of monthly heavy drinking days. Trial was withdrawn before enrolling any participants, generating no clinical data. Represents a negative signal both for feasibility and for relevance to the insomnia indication.

Literature Evidence

PMID	Year	Type	Journal	Key Findings
36931805	2023	RCT	The Lancet Neurology	Phase 3 RCT in children ≥6 years with narcolepsy; pitolisant demonstrated safety and efficacy for excessive daytime sleepiness and cataplexy. Entirely narcolepsy-focused — not insomnia.
33121980	2021	RCT	Chest	Pitolisant reduced residual excessive daytime sleepiness in OSA patients adherent to CPAP. Demonstrates a wake-promoting effect — the opposite of insomnia treatment.
31917607	2020	RCT	Am J Respir Crit Care Med	International RCT of pitolisant for daytime sleepiness in moderate-to-severe OSA patients refusing CPAP; confirmed wake-promoting efficacy. No insomnia data.
36169322	2022	Cohort (Real-world)	Revista de neurologia	Real-world study in type 1 narcolepsy patients unresponsive to prior standard treatments; pitolisant showed effectiveness and tolerability in this refractory population.
34521328	2022	Review	Current Neuropharmacology	Reviews histaminergic system changes in neuropsychiatric disorders; explicitly contrasts pitolisant (H3R inverse agonist → wakefulness) with doxepin (H1R antagonist → insomnia treatment) — highlights the mechanistic incompatibility with the predicted indication.
34225942	2021	Review	Handbook of Clinical Neurology	Comprehensive overview of all four histamine receptor subtypes and their drug targets; provides mechanistic foundation for H3R pharmacology in the brain.
30214155	2018	Review	Drug Design, Development and Therapy	Profile of pitolisant for narcolepsy management; confirms European authorization and characterises H3 inverse agonism as the drug's defining mechanism.
22356925	2012	Review/Mechanism	Clinical Neuropharmacology	Pitolisant as an alternative stimulant for adolescents with narcolepsy refractory to conventional therapy; underscores the wakefulness-enhancement mechanism via H3 autoreceptor blockade.

Italy Market Information

Pitolisant currently has no registered authorizations in Italy (0 licenses). The drug is not marketed locally.

Note: Pitolisant (brand name Wakix) has received EMA approval for narcolepsy with or without cataplexy in adults, and subsequently for children aged 6 and above (EMA/CHMP). It has also been approved by the FDA (2019) for excessive daytime sleepiness in adult narcolepsy. These international approvals are not reflected in the local authorization database queried for this report.

Safety Considerations

Please refer to the package insert for safety information.

Conclusion and Next Steps

Decision: Hold

Rationale: Pitolisant's core pharmacological action — promoting wakefulness through histamine H3 receptor inverse agonism — is directionally incompatible with insomnia treatment, which requires facilitation of sleep rather than arousal. The sole retrieved clinical trial was withdrawn with zero enrollment and was targeting a completely different indication (alcohol use disorder), and all eight publications in the literature corpus address narcolepsy or excessive daytime sleepiness. The TxGNN high score almost certainly reflects false-positive graph topology between sleep disorders rather than genuine repurposing potential.

To proceed, the following is needed:

A credible mechanistic hypothesis explaining how a wake-promoting agent could paradoxically benefit insomnia patients (e.g., circadian resetting, rebound sleep induction, or a specific insomnia subtype such as hyperarousal-related insomnia — none of which are currently supported by evidence)
De novo clinical trial data specifically in insomnia populations; no such trials exist
Safety profiling for insomnia patients, who differ substantially from the narcolepsy population in sleep architecture, comorbidities, and concomitant medication use
Reassessment of TxGNN model performance on the sleep disorder subgraph to quantify the systematic false-positive rate for pharmacodynamically opposing indications
Disclaimer

This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.